Current Research & Development

INOmax® (nitric oxide) for Inhalation
Pulmonary hypertension is an underlying cause of many critical conditions. When blood vessels in the lungs become constricted, elevated pressures can lead to inadequate oxygenation. Inspired by the promise of nitric oxide, our research and development program continues to expand the possibilities.
Read More

Lucassin® (terlipressin)
Hepatorenal syndrome, or HRS Type 1, is a rare and often fatal condition of advancing kidney failure in patients with cirrhosis or other severe liver diseases. In many of these patients, a successful liver transplant is their only hope to reverse HRS Type I and restore normal kidney function.
Read More

IK-5001
IK-5001 is a potential treatment for preventing cardiac remodelling and subsequent congestive heart failure following acute myocardial infarction.
Read More

Delivery Systems
Ikaria’s hands-on understanding of the critical care environment helps us design at an optimum level. Beyond providing novel biotherapeutics, Ikaria also has expertise in developing drug-delivery systems.
Read More